Deficiency of protein C in congenital thrombotic disease. JH Griffin, B Evatt, TS Zimmerman, AJ Kleiss, C Wideman The Journal of clinical investigation 68 (5), 1370-1373, 1981 | 1841 | 1981 |
The cytoprotective protein C pathway LO Mosnier, BV Zlokovic, JH Griffin Blood 109 (8), 3161-3172, 2007 | 912 | 2007 |
Endothelial and antithrombotic actions of HDL C Mineo, H Deguchi, JH Griffin, PW Shaul Circulation research 98 (11), 1352-1364, 2006 | 804 | 2006 |
Protein synthesis by native chemical ligation: expanded scope by using straightforward methodology TM Hackeng, JH Griffin, PE Dawson Proceedings of the National Academy of Sciences 96 (18), 10068-10073, 1999 | 799 | 1999 |
Plasma protein S deficiency in familial thrombotic disease HP Schwarz, M Fischer, P Hopmeier, MA Batard, JH Griffin Blood 64 (6), 1297-1300, 1984 | 750 | 1984 |
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective T Cheng, D Liu, JH Griffin, JA Fernández, F Castellino, ED Rosen, ... Nature medicine 9 (3), 338-342, 2003 | 729 | 2003 |
Anticoagulant protein C pathway defective in majority of thrombophilic patients JH Griffin, B Evatt, C Wideman, JA Fernandez Blood 82 (7), 1989-1993, 1993 | 687 | 1993 |
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme RA Marlar, AJ Kleiss, JH Griffin Blood 59 (5), 1067-1072, 1982 | 572 | 1982 |
Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial Apex AMI Investigators Jama 297 (1), 43-51, 2007 | 523 | 2007 |
Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant HE Branson, R Marble, J Katz, JH Griffin The Lancet 322 (8360), 1165-1168, 1983 | 462 | 1983 |
Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V CA Fulcher, JE Gardiner, JH Griffin, TS Zimmerman Blood 63 (2), 486-489, 1984 | 448 | 1984 |
Human blood coagulation factor XI. Purification, properties, and mechanism of activation by activated factor XII. BN Bouma, JH Griffin Journal of Biological Chemistry 252 (18), 6432-6437, 1977 | 422 | 1977 |
Activated protein C resistance caused by Arg506Gln mutation in factor Va JS Greengard, X Sun, X Xu, JA Fernandez, JH Griffin, B Evatt The Lancet 343 (8909), 1361-1362, 1994 | 421 | 1994 |
Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII) JH Griffin Proceedings of the National Academy of Sciences 75 (4), 1998-2002, 1978 | 406 | 1978 |
Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. JH Griffin, CG Cochrane Proceedings of the National Academy of Sciences 73 (8), 2554-2558, 1976 | 403 | 1976 |
Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles G Tans, J Rosing, MC Thomassen, MJ Heeb, RF Zwaal, JH Griffin | 392 | 1991 |
Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C EJ Kerschen, JA Fernandez, BC Cooley, XV Yang, R Sood, LO Mosnier, ... The Journal of experimental medicine 204 (10), 2439-2448, 2007 | 361 | 2007 |
The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis CL Gladson, I Scharrer, V Hach, KH Beck, JH Griffin Thrombosis and haemostasis 59 (01), 018-022, 1988 | 344 | 1988 |
Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Y Sakata, S Curriden, D Lawrence, JH Griffin, DJ Loskutoff Proceedings of the National Academy of Sciences 82 (4), 1121-1125, 1985 | 329 | 1985 |
High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C JH Griffin, K Kojima, CL Banka, LK Curtiss, JA Fernández The Journal of clinical investigation 103 (2), 219-227, 1999 | 322 | 1999 |